Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells
Pneumologie · 01.02.2025 · 79 (02) · 134-140
DOI: 10.1055/a-2372-3632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pneumologie, erschienen am 01.02.2025. Verfasst von Gudrun Sigrid Ulrich-Merzenich und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III, AG Synergy Research and Experimental Medicine, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Interleukin-6, Dexamethasone, Angiotensin-Converting Enzyme 2, Azithromycin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
The optimal use of steroids in COVID-19 patients remains challenging. Current S3-guidelines “Recommendations for patients with COVID-19” recommend dexamethasone (DEX) for patients requiring respiratory support, remdesivir (RD) in the early disease phase and azythromycin (AZ) is no longer recommended. We investigated effects of DEX, RD and AZ in a lipopolysaccharide induced inflammation in lung cells in vitro and analyzed publicly available datasets with a focus on the Angiotensin-converting enzyme 2 (ACE2) to better understand drugs’ mechanisms of action. Methods human bronchial (Calu) and alveolar (A549) lung epithelial cells were treated with DEX, AZ or RDV in the presence of lipopolysaccharides (LPS). Gene expression (GE) of ACE2, IL-6 and the IL-6 protein release were measured. Publicly available GE data from lung tissues of COVID-19 patients and from lung cells treated with DEX were analyzed for the GE of ACE2.
Results
DEX increased and RDV and AZ reduced the GE of ACE2 in LPS-stimulated bronchial and alveolar epithelial cells. Only DEX significantly reduced LPS-induced IL-6 releases in alveolar cells substantially. The database analyses showed an, albeit not always significant, increase in ACE2 for lung tissue or cell lines treated with DEX. Lung tissue from patients after COVID-19 infection as well as bronchial cell cultures after COVID-19 infection showed lower GEs of ACE2. Discussion and Conclusion DEX can increase ACE2 expression in vitro and thereby the portal of entry of SARS-CoV-2 into lung cells during an LPS induced inflammation. Simultaneously the inflammatory marker IL-6 is reduced. Comparative database analyses indicate that these processes can also take place in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Clinic III, AG Synergy Research and Experimental Medicine, University Hospital Bonn, Bonn, Germany.
- Department Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Zitieren
APA
Ulrich-Merzenich, G. S., Shcherbakova, A., Pizarro, C., & Skowasch, D. (2025). Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells. Pneumologie, 79(02), 134-140. https://doi.org/10.1055/a-2372-3632
Vancouver
Ulrich-Merzenich GS, Shcherbakova A, Pizarro C, Skowasch D. Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells. Pneumologie. 2025;79(02):134-140. doi:10.1055/a-2372-3632
BibTeX
@article{UlrichMerzenich2025,
author = {Ulrich-Merzenich, Gudrun Sigrid and Shcherbakova, Anastasiia and Pizarro, Carmen and Skowasch, Dirk},
title = {Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells},
journal = {Pneumologie},
year = {2025},
volume = {79},
number = {02},
pages = {134--140},
doi = {10.1055/a-2372-3632}
}
EUVIMED